

Renata Mikolajczak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689692/publications.pdf>

Version: 2024-02-01

90
papers

1,755
citations

257450

24
h-index

302126

39
g-index

95
all docs

95
docs citations

95
times ranked

1744
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1788-1797.	6.4	211
2	Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1049-1062.	6.4	113
3	Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 524-531.	6.4	96
4	Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1669-1674.	6.4	89
5	Initial Direct Comparison of ^{99m} Tc-TOC and ^{99m} Tc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1060-1065.	5.0	55
6	⁴⁴ Sc-DOTA-BN[2-14]NH ₂ in comparison to ⁶⁸ Ga-DOTA-BN[2-14]NH ₂ in pre-clinical investigation. Is ⁴⁴ Sc a potential radionuclide for PET?. <i>Applied Radiation and Isotopes</i> , 2012, 70, 2669-2676.	1.5	49
7	Radiometals for imaging and theranostics, current production, and future perspectives. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 615-634.	1.0	49
8	Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. <i>Annals of Nuclear Medicine</i> , 2017, 31, 347-356.	2.2	47
9	Somatostatin receptor scintigraphy using ^{99m} Tc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1635-1645.	6.4	45
10	Semiquantitative Analysis and Characterization of Physiological Biodistribution of ⁶⁸ Ga-DOTA-TATE PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1052-1057.	1.3	43
11	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with ¹¹¹ In-CP04 in medullary thyroid carcinoma patients. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 91, 236-242.	4.0	43
12	Activation cross sections for reactions induced by 14 MeV neutrons on natural tin and enriched ¹¹² Sn targets with reference to ¹¹¹ In production via radioisotope generator ¹¹² Sn(n, 2n) ¹¹¹ Sn. <i>Radiochimica Acta</i> , 2005, 93, 311-326.	1.2	39
13	Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope ⁹⁰ Y-DOTA TATE, ¹⁷⁷ Lu-DOTA TATE or ⁹⁰ Y/ ¹⁷⁷ Lu-DOTA TATE therapy in patients with disseminated NET. <i>Radiotherapy and Oncology</i> , 2012, 102, 45-50.	0.6	39
14	Clinical usefulness of ^{99m} Tc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1402-1406.	6.4	38
15	Patient-Specific Radiation Dosimetry of ^{99m} Tc-HYNIC-Tyr ³ -Octreotide in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1474-1481.	5.0	37
16	Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [^{99m} Tc-EDDA-HYNIC-D-Phe ¹ , Tyr ³]-octreotide, a somatostatin analog for tumor diagnosis. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2497-2506.	3.3	36
17	Radiopharmaceuticals for somatostatin receptor imaging. <i>Nuclear Medicine Review</i> , 2016, 19, 126-132.	0.5	33
18	Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 673-683.	1.0	31

#	ARTICLE	IF	CITATIONS
19	Tandem peptide receptor radionuclide therapy using ⁹⁰ Y/ ¹⁷⁷ Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 922-933.	6.4	31
20	Comparative study on DOTA-derivatized bombesin analog labeled with ⁹⁰ Y and ¹⁷⁷ Lu: in vitro and in vivo evaluation. <i>Nuclear Medicine and Biology</i> , 2009, 36, 591-603.	0.6	30
21	^{99m} Tc Labeled Glucagon-Like Peptide-1-Analogue (^{99m} Tc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma. <i>PLoS ONE</i> , 2016, 11, e0160714.	2.5	30
22	From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 85, 1-9.	4.0	29
23	Comparison of receptor affinity of natSc-DOTA-TATE versus natGa-DOTA-TATE. <i>Nuclear Medicine Review</i> , 2011, 14, 85-89.	0.5	26
24	^{99m} Tc-EDDA/HYNIC-TOC in the Management of Medullary Thyroid Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 211-217.	1.0	24
25	^{99m} Tc-EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1005-1010.	6.4	23
26	Glucagon-Like Peptide-1 Receptor Imaging with [⁴⁰ K]Ahx-HYNIC- ^{99m} Tc/EDDA)NH ₂ -Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-6.	1.5	23
27	Initial Study of Radiological and Clinical Efficacy Radioembolization Using ¹⁸⁸ Re-Human Serum Albumin (HSA) Microspheres in Patients with Progressive, Unresectable Primary or Secondary Liver Cancers. <i>Medical Science Monitor</i> , 2014, 20, 1353-1362.	1.1	22
28	Chemistry and bifunctional chelating agents for binding ¹⁷⁷ Lu. <i>Current Radiopharmaceuticals</i> , 2015, 8, 86-94.	0.8	19
29	Comparison of PET/CT imaging with [¹⁸ F]FDOPA and cholecystokinin-2 receptor targeting [⁶⁸ Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 935-936.	6.4	18
30	Clinical Usefulness of ^{99m} Tc-EDDA/HYNIC-TOC Scintigraphy in Oncological Diagnostics: A Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 261-270.	1.0	16
31	A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma " GRAN-T-MTC " a multicenter phase I study. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 791-795.	0.4	16
32	Rak rdzeniasty tarczycy " badanie PET/CT ze znakowanymi ⁶⁸ Ga analogami gastryny i somatostatyny. <i>Endokrynologia Polska</i> , 2016, 67, 68-71.	1.0	15
33	Kit with technetium- ^{99m} labelled antimicrobial peptide UBI 29-41 for specific infection detection. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2005, 48, 683-691.	1.0	14
34	[^{99m} Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes. <i>Cancers</i> , 2021, 13, 5093.	3.7	14
35	Differential diagnosis of solitary pulmonary nodules based on ^{99m} Tc-EDDA/HYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1041-1047.	6.4	13
36	Two Peptide Receptor Ligands ^{99m} Tc-EDDA/HYNIC-Tyr ³ -Octreotide and ^{99m} Tc-EDDA/HYNIC-D-Glu-Octagastrin for Scintigraphy of Medullary Thyroid Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 613-628.	1.0	13

#	ARTICLE	IF	CITATIONS
37	A Frequency and Semiquantitative Analysis of Pathological ⁶⁸ Ga DOTATATE PET/CT Uptake by Primary Site-Dependent Neuroendocrine Tumor Metastasis. <i>Clinical Nuclear Medicine</i> , 2014, 39, 855-861.	1.3	13
38	IAEA Activities on ⁶⁷ Cu, ¹⁸⁶ Re, ⁴⁷ Sc Theranostic Radionuclides and Radiopharmaceuticals. <i>Current Radiopharmaceuticals</i> , 2021, 14, 306-314.	0.8	13
39	Identification of Inflamed Atherosclerotic Plaque using ¹²³ I-Labeled Interleukin-2 Scintigraphy in High-Risk Peritoneal Dialysis Patients: A Pilot Study. <i>Peritoneal Dialysis International</i> , 2009, 29, 568-574.	2.3	11
40	Investigation of ^{99m} Tc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide. <i>Nuclear Medicine and Biology</i> , 2010, 37, 795-803.	0.6	11
41	Evaluation of dead-time corrections for post-radionuclide-therapy ¹⁷⁷ Lu quantitative imaging with low-energy high-resolution collimators. <i>Nuclear Medicine Communications</i> , 2014, 35, 73-87.	1.1	11
42	¹⁷⁷ Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation. <i>Molecular Pharmaceutics</i> , 2017, 14, 3045-3058.	4.6	11
43	Standardization of Procedures for the Preparation of ¹⁷⁷ Lu- and ⁹⁰ Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation. <i>Current Radiopharmaceuticals</i> , 2015, 8, 62-68.	0.8	10
44	Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?. <i>Nuclear Medicine Review</i> , 2011, 14, 73-78.	0.5	10
45	Oxidation of methionine is it limiting the diagnostic properties of ^{99m} Tc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?. <i>Nuclear Medicine Review</i> , 2016, 19, 104-110.	0.5	10
46	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. <i>Cancers</i> , 2021, 13, 5776.	3.7	10
47	Application of AnaLig resin for ^{99m} Tc separation from ¹⁰⁰ Mo target irradiated in cyclotron. <i>Applied Radiation and Isotopes</i> , 2016, 113, 75-78.	1.5	9
48	Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor. <i>EJNMMI Research</i> , 2018, 8, 33.	2.5	9
49	Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys40(AhxHYNIC-[^{99m} Tc]/EDDA)NH2]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma. <i>Molecular Imaging and Biology</i> , 2020, 22, 165-172.	2.6	9
50	Polish Experience in Peptide Receptor Radionuclide Therapy. <i>Recent Results in Cancer Research</i> , 2013, 194, 467-478.	1.8	9
51	Lu-177-Labeled Zirconia Particles for Radiation Synovectomy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 433-438.	1.0	8
52	Design and Evaluation of ²²³ Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy-Part II. Toxicity, Pharmacokinetics and Biodistribution. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5702.	4.1	8
53	Selection of the First ^{99m} Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates. <i>Pharmaceutics</i> , 2021, 14, 19.	3.8	8
54	The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y. <i>Nuclear Medicine Review</i> , 2015, 18, 51-55.	0.5	8

#	ARTICLE	IF	CITATIONS
55	Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. <i>Nuclear Medicine Review</i> , 2016, 19, 88-92.	0.5	8
56	Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 673-682.	6.4	7
57	Determination of 90Sr traces in medical 90Y after separation on DGA column. <i>Talanta</i> , 2013, 114, 1-4.	5.5	7
58	PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2731.	4.1	7
59	Studies on the separation of 99mTc from large excess of molybdenum. <i>Nuclear Medicine Review</i> , 2015, 18, 65-69.	0.5	7
60	Synthesis of novel halo and tosyloxy nortropane derivatives as efficient precursors for the one-step synthesis of the dopamine transporter PET ligand [¹⁸ F]FECNT. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 148-157.	1.0	6
61	Manufacturing and characterization of molybdenum pellets used as targets for 99m Tc production in cyclotron. <i>Applied Radiation and Isotopes</i> , 2017, 124, 124-131.	1.5	6
62	Radiopharmaceuticals in cardiology. <i>Nuclear Medicine Review</i> , 2012, 15, 39-45.	0.5	6
63	Comparison of separation methods for 47Ca/47Sc radionuclide generator. <i>Applied Radiation and Isotopes</i> , 2019, 151, 140-144.	1.5	5
64	SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers. <i>Pharmaceuticals</i> , 2021, 14, 300.	3.8	5
65	Clickable Radiocomplexes With Trivalent Radiometals for Cancer Theranostics: In vitro and in vivo Studies. <i>Frontiers in Medicine</i> , 2021, 8, 647379.	2.6	5
66	Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. <i>Peritoneal Dialysis International</i> , 2009, 29, 568-74.	2.3	5
67	Short Communication: Semiquantitative Assessment of 99mTc-EDDA/HYNIC-TOC Scintigraphy in Differentiation of Solitary Pulmonary Nodules – a Complementary Role to Visual Analysis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 61-67.	1.0	4
68	The penetration of topically applied ointment containing hyaluronic acid in rabbit tissues. <i>Polish Journal of Veterinary Sciences</i> , 2011, 14, 621-7.	0.2	4
69	Impact of DOTA-Chelators on the Antitumor Activity of ¹⁷⁷ Lu-DOTA-Rituximab Preparations in Lymphoma Tumor-Bearing Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 558-562.	1.0	4
70	Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations. <i>Nuclear Medicine and Biology</i> , 2021, 93, 63-73.	0.6	4
71	Radiopharmaceuticals in cardiology. <i>Nuclear Medicine Review</i> , 2012, 15, 39-45.	0.5	3
72	Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of Lu- and Y-Rituximab in Xenografted Mice. <i>Iranian Journal of Pharmaceutical Research</i> , 2018, 17, 1201-1208.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Dosimetry of exendin-4 based radiotracer for glucagonlike peptide-1 receptor imaging: an initial report. <i>Journal of Physics: Conference Series</i> , 2011, 317, 012011.	0.4	2
74	New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc99m Exametazime. <i>Nuclear Medicine Review</i> , 2017, 20, 88-94.	0.5	2
75	Radionuclide generators. , 2021, , .		1
76	Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
77	Investigation of the 188Re Eluate Suitability for Medical Purposes by Labeling a Bombesin Analog (BN1.1). <i>Current Radiopharmaceuticals</i> , 2009, 2, 295-303.	0.8	1
78	Improved procedures of Sc(OH)3 precipitation and UTEVA extraction for 44Sc separation. <i>Nuclear Medicine Review</i> , 2019, 22, 56-59.	0.5	1
79	Recombinant fragment of an antibody tailored for direct radioiodination. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 52-56.	1.0	0
80	A one-step automated synthesis of the dopamine transporter ligand [¹⁸ F]FECNT from the chlorinated precursor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 82-86.	1.0	0
81	In memoriam " Prof. Anna Celler. <i>Nuclear Medicine Review</i> , 2021, 24, 37-39.	0.5	0
82	An approach towards reverse generator system for 99mTc separation from LSA 99Mo. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S97.	0.6	0
83	Studies on the novel scandium-47 labelled PSMA inhibitor targeting ligand. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S102.	0.6	0
84	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 31.	3.9	0
85	Six-years experience in the treatment of the neuroendocrine tumors with the use of peptide receptor radionuclide therapy (PRRT). <i>Endocrine Abstracts</i> , 0, , .	0.0	0
86	Patient with dissemination of neuroendocrine neoplasm of unknown origin and carcinoid syndrome: diagnostic and therapeutic difficulties. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
87	99mTc-GLP-1 scintigraphy, an efficient method for the detection of insulinoma: results of 3 years' experience. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
88	Combined therapy PRRT with long acting somatostatin analogue: results of 7 years' experience. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
89	Peptide receptor radionuclide therapy as neoadjuvant treatment. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
90	Could 99mTc labelled glucagon-like peptide 1 analogue scintigraphy be an answer for patients with persistent hypoglycaemia?. <i>Endocrine Abstracts</i> , 0, , .	0.0	0